S'abonner

Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults - 28/09/23

Doi : 10.1016/S1473-3099(23)00210-4 
Nicole Bézay, PhD a, Romana Hochreiter, PhD a, Vera Kadlecek, MSc a, Nina Wressnigg, PhD a, Julian Larcher-Senn, PhD b, Anton Klingler, PhD b, Katrin Dubischar, MSc a, Susanne Eder-Lingelbach, MSc a, , Isabel Leroux-Roels, ProfMD c, Geert Leroux-Roels, ProfMD c, Wolfgang Bender, MD a
a Valneva Austria, Campus Vienna Biocenter 3, Vienna, Austria 
b Assign Data Management and Biostatistics, Innsbruck, Austria 
c Center for Vaccinology (CEVAC), Ghent University Hospital, 9000 Ghent, Belgium 

* Correspondence to: Susanne Eder-Lingelbach, Valneva Austria, Campus Vienna Biocenter 3, 1030 Vienna, Austria Valneva Austria Campus Vienna Biocenter 3 Vienna 1030 Austria

Summary

Background

Lyme borreliosis, potentially associated with serious long-term complications, is caused by the species complex Borrelia burgdorferi sensu lato. We investigated a novel Lyme borreliosis vaccine candidate (VLA15) targeting the six most common outer surface protein A (OspA) serotypes 1–6 to prevent infection with pathogenic Borrelia spp prevalent in Europe and North America.

Methods

This was a partially randomised, observer-masked, phase 1 study in healthy adults older than 18 years to younger than 40 years (n=179) done in trial sites in Belgium and the USA. Following a non-randomised run-in phase, a sealed envelope randomisation method was applied with a 1:1:1:1:1:1 ratio; three dose concentrations of VLA15 (12 μg, 48 μg, and 90 μg) were administered by intramuscular injection on days 1, 29, and 57. The primary outcome was safety (frequency of adverse events up to day 85) assessed in participants who received at least one vaccination. Immunogenicity was a secondary outcome. The trial is registered with ClinicalTrials.gov, NCT03010228, and is complete.

Findings

Between Jan 23, 2017 and Jan 16, 2019, of 254 participants screened for eligibility, 179 were randomly assigned into six groups: alum-adjuvanted 12 μg (n=29), 48 μg (n=31), or 90 μg (n=31) and non-adjuvanted 12 μg (n=29 participants), 48 μg (n=29), or 90 μg (n=30). VLA15 was safe and well tolerated and the majority of adverse events were mild or moderate. Overall, adverse events were more frequent in the 48 μg and 90 μg groups (range 28−30 participants [94−97%]) when compared with the 12 μg group (25 [86%] participants, 95% CI 69·4–94·5) for adjuvanted and non-adjuvanted groups. Common local reactions were tenderness (151 [84%] participants; 356 events, 95% CI 78·3−89·4) and injection site pain (120 [67%]; 224 events, 59·9–73·5); most frequent systemic reactions were headache (80 [45%]; 112 events, 37·6–52·0), excessive fatigue (45 [25%]; 56 events, 19·4–32·0), and myalgia (45 [25%]; 57 events, 19·4–32·0). A similar safety and tolerability profile was observed between adjuvanted and non-adjuvanted formulations. The majority of solicited adverse events were mild or moderate. VLA15 was immunogenic for all OspA serotypes with higher immune responses induced in the adjuvanted higher dose groups (geometric mean titre range 90 μg with alum 61·3 U/mL–321·7 U/mL vs 23·8 U/mL–111·5 U/mL at 90 μg without alum).

Interpretation

This novel multivalent vaccine candidate against Lyme borreliosis was safe and immunogenic and paves the way to further clinical development.

Funding

Valneva Austria.

Le texte complet de cet article est disponible en PDF.

Plan


© 2023  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 23 - N° 10

P. 1186-1196 - octobre 2023 Retour au numéro
Article précédent Article précédent
  • Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial
  • Michael A Koren, Leyi Lin, Kenneth H Eckels, Rafael De La Barrera, Vincent Dussupt, Gina Donofrio, Erica L Sondergaard, Kristin T Mills, Merlin L Robb, Christine Lee, Oluwaseun Adedeji, Paul B Keiser, Justin M Curley, Nathanial K Copeland, Trevor A Crowell, Jack N Hutter, Melinda J Hamer, Anais Valencia-Ruiz, Janice Darden, Sheila Peel, Mihret F Amare, Tsedal Mebrahtu, Margaret Costanzo, Shelly J Krebs, Gregory D Gromowski, Richard G Jarman, Stephen J Thomas, Nelson L Michael, Kayvon Modjarrad
| Article suivant Article suivant
  • Trends in invasive Haemophilus influenzae serotype a disease in England from 2008–09 to 2021–22: a prospective national surveillance study
  • Marta Bertran, Joshua C D’Aeth, Erjola Hani, Zahin Amin-Chowdhury, Norman K Fry, Mary E Ramsay, David J Litt, Shamez N Ladhani

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.